HowardLSofenMD
Dermatology • Los Angeles, CAMedical Director of Dermatology Research Associates; Associate Clinical Professor of Medicine/Dermatology Geffen School of Medicine, UCLA
Dr. Sofen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8930 S Sepulveda Blvd
Ste 114
Los Angeles, CA 90045Phone+1 310-337-7171Fax+1 310-337-1081
Summary
- Dr. Howard Sofen is a dermatologist in Los Angeles, CA and is affiliated with Ronald Reagan UCLA Medical Center. He received his medical degree from Drexel University College of Medicine and has been in practice 36 years. He is experienced in general dermatology, melanoma and cutaneous malignancies, and psoriasis; eczema.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Dermatology, 1982 - 1985
University of Southern California/Los Angeles General Medical Center (USC/LA General)Internship, Internal Medicine, 1981 - 1982
Drexel University College of MedicineClass of 1981
Certifications & Licensure
CA State Medical License 1982 - 2025
American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- Fellow (FAAD) American Academy of Dermatology
Clinical Trials
- The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Start of enrollment: 2009 Nov 01
- Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris Start of enrollment: 2014 Mar 19
- A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis Start of enrollment: 2015 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials.Joseph F Merola, Laura K Ferris, Jeffrey M Sobell, Howard Sofen, John Osborne
Dermatology and Therapy. 2025-02-07 - Phase II Randomized Trial of BI 730357, a Novel Oral RORγt Inhibitor, for Moderate-to-Severe Plaque Psoriasis.Melinda J Gooderham, Ulrich Mrowietz, Werner Kadus, Kristin Drda, Hui Gu
The Journal of Investigative Dermatology. 2025-01-21 - Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children.Eric L Simpson, Adelaide A Hebert, John Browning, Rocco T Serrao, Howard Sofen
Dermatology and Therapy. 2025-01-01
Press Mentions
Tildrakizumab Shows Durable Response in Scalp PsoriasisDecember 30th, 2024- Top 5 Small Cosmetic Dermatology SitesMay 4th, 2023
- Asana BioSciences to Present Additional Efficacy Data from Chronic Hand Eczema Phase 2b Trial of Oral SYK/JAK Inhibitor Gusacitinib at AAD VMX Late-Breaking SessionApril 22nd, 2021
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
